The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Bio-Techne Corp’s stock clocked out at $50.48, down -1.44% from its previous closing price of $51.22. In other words, the price has decreased by -$1.44 from its previous closing price. On the day, 2.46 million shares were traded. TECH stock price reached its highest trading level at $51.38 during the session, while it also had its lowest trading level at $50.13.
Ratios:
To gain a deeper understanding of TECH’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 48.41 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 30.61. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 3.46. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.22.
On August 21, 2025, Citigroup Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $70.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 25 ’25 when Nusse Roeland sold 17,040 shares for $56.36 per share. The transaction valued at 960,388 led to the insider holds 44,559 shares of the business.
BAUMGARTNER ROBERT V sold 17,040 shares of TECH for $957,818 on Aug 25 ’25. The Director now owns 44,863 shares after completing the transaction at $56.21 per share. On Aug 25 ’25, another insider, ROELAND NUSSE, who serves as the Director of the company, bought 17,040 shares for $56.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TECH now has a Market Capitalization of 7859404800 and an Enterprise Value of 8134014976. As of this moment, Bio-Techne’s Price-to-Earnings (P/E) ratio for their current fiscal year is 111.31, and their Forward P/E ratio for the next fiscal year is 22.35. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 9.80. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.44 while its Price-to-Book (P/B) ratio in mrq is 4.08. Its current Enterprise Value per Revenue stands at 6.669 whereas that against EBITDA is 24.564.
Stock Price History:
The Beta on a monthly basis for TECH is 1.47, which has changed by -0.35873985 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, TECH has reached a high of $80.80, while it has fallen to a 52-week low of $46.01. The 50-Day Moving Average of the stock is -6.13%, while the 200-Day Moving Average is calculated to be -13.80%.
Shares Statistics:
It appears that TECH traded 2.23M shares on average per day over the past three months and 2553240 shares per day over the past ten days. A total of 154.97M shares are outstanding, with a floating share count of 153.75M. Insiders hold about 1.16% of the company’s shares, while institutions hold 102.98% stake in the company. Shares short for TECH as of 1756425600 were 5124437 with a Short Ratio of 2.36, compared to 1753920000 on 6335952. Therefore, it implies a Short% of Shares Outstanding of 5124437 and a Short% of Float of 3.7900000000000005.
Dividends & Splits
With its trailing 12-month dividend rate of 0.32, TECH has a forward annual dividend rate of 0.32. Against a Trailing Annual Dividend Yield of 0.006247559. The stock’s 5-year Average Dividend Yield is 0.41. The current Payout Ratio is 69.67% for TECH, which recently paid a dividend on 2025-08-18 with an ex-dividend date of 2025-08-18. Stock splits for the company last occurred on 2022-11-30 when the company split stock in a 4:1 ratio.
Earnings Estimates
A detailed examination of Bio-Techne Corp (TECH) is currently in progress, with 13.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.46, with high estimates of $0.5 and low estimates of $0.43.
Analysts are recommending an EPS of between $2.13 and $1.91 for the fiscal current year, implying an average EPS of $2.01. EPS for the following year is $2.24, with 14.0 analysts recommending between $2.44 and $2.01.
Revenue Estimates
In the current quarter, 13 analysts expect revenue to total $292.75M. It ranges from a high estimate of $298M to a low estimate of $289.52M. As of the current estimate, Bio-Techne Corp’s year-ago sales were $289.46MFor the next quarter, 13 analysts are estimating revenue of $300.07M. There is a high estimate of $306M for the next quarter, whereas the lowest estimate is $296.13M.
A total of 15 analysts have provided revenue estimates for TECH’s current fiscal year. The highest revenue estimate was $1.26B, while the lowest revenue estimate was $1.23B, resulting in an average revenue estimate of $1.24B. In the same quarter a year ago, actual revenue was $1.22BBased on 13 analysts’ estimates, the company’s revenue will be $1.33B in the next fiscal year. The high estimate is $1.36B and the low estimate is $1.29B.
